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Abstract
Antihypertensive drugs are among the most commonly prescribed drugs for chronic disease worldwide. The response to
antihypertensive drugs varies substantially between individuals and important factors such as race that contribute to this
heterogeneity are poorly understood. In this study we use metabolomics, a global biochemical approach to investigate
biochemical changes induced by the beta-adrenergic receptor blocker atenolol in Caucasians and African Americans.
Plasma from individuals treated with atenolol was collected at baseline (untreated) and after a 9 week treatment period and
analyzed using a GC-TOF metabolomics platform. The metabolomic signature of atenolol exposure included saturated
(palmitic), monounsaturated (oleic, palmitoleic) and polyunsaturated (arachidonic, linoleic) free fatty acids, which decreased
in Caucasians after treatment but were not different in African Americans (p,0.0005, q,0.03). Similarly, the ketone body 3-
hydroxybutyrate was significantly decreased in Caucasians by 33% (p,0.0001, q,0.0001) but was unchanged in African
Americans. The contribution of genetic variation in genes that encode lipases to the racial differences in atenolol-induced
changes in fatty acids was examined. SNP rs9652472 in LIPC was found to be associated with the change in oleic acid in
Caucasians (p,0.0005) but not African Americans, whereas the PLA2G4C SNP rs7250148 associated with oleic acid change
in African Americans (p,0.0001) but not Caucasians. Together, these data indicate that atenolol-induced changes in the
metabolome are dependent on race and genotype. This study represents a first step of a pharmacometabolomic approach
to phenotype patients with hypertension and gain mechanistic insights into racial variability in changes that occur with
atenolol treatment, which may influence response to the drug.
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Introduction
Hypertension is the most common chronic disease world-wide
with an estimated one billion individuals affected [1]. The cause of
blood pressure elevation is not known in the vast majority of
patients with essential hypertension, thus it is difficult to project
prognosis or predict optimal treatment in an individual patient.
Although multiple antihypertensive drug classes are available for
treatment of hypertension, only about 50% of individuals have
adequate blood pressure (BP) lowering with any given drug
therapy and less than 40% of hypertensive patients have controlled
BP [2,3]. Additionally, there are well defined differences in drug
response by race but mechanisms underlying these differences in
response are poorly understood.
b-blockers such as atenolol are important first line antihyper-
tensive treatment, but not all patients respond and these drugs are
associated with adverse metabolic effects, specifically adverse
changes in glucose, triglycerides and uric acid, all of which can
have negative cardiovascular consequences long-term [4,5].
Unfortunately, there are no well-defined biomarkers to identify
patients that will have a beneficial therapeutic response or
experience the adverse metabolic consequences of these drugs.
Metabolomics is a global biochemical approach that provides
powerful tools for defining perturbations in metabolic pathways
and networks in human disease [6–10]. The metabolome defines a
metabolic state as regulated by net interactions between gene and
environmental influences and provides information that can
possibly bridge the gap between genotype and phenotype.
Targeted and non-targeted metabolomic approaches have been
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used to define pathways implicated in variation of response to
drugs such as escitalopram [11] and simvastatin [12,13] leading to
the emergence of a new field: pharmacometabolomics [9,14,15].
Indeed, pharmacometabolomics can be used to define a unique
signature that represents changes in the metabolome induced by
drug treatment. This signature can provide insight into the
mechanism of variation in drug response caused by factors
including race and genetics.
In the present study, a mass spectrometry based global
metabolomics approach was used to analyze effects of the b-
blocker atenolol in patients participating in the Pharmacogenomic
Evaluation of Antihypertensive Responses (PEAR) study [16].
PEAR is a randomized clinical trial designed to identify genetic
determinants of blood pressure and adverse metabolic responses to
a thiazide diuretic and b-blocker. Responses to the b1-selective
blocker atenolol or the diuretic hydrochlorothiazide as monother-
apy and then in combination were determined in 768 patients with
mild to moderate hypertension. Metabolomic analyses were
conducted in a subset of 272 patients receiving atenolol
monotherapy. The objective of this study was to characterize the
metabolomic signature of drug treatment as a first step to
determine whether metabolomics might provide novel mechanistic
insight into racial differences in response to b-blockers. Because
the analysis showed a strong fatty acid signature that also differed
by race, we tested the hypothesis that genetic variation in genes
encoding lipases might be associated with observed atenolol-
induced changes in different racial groups.
Materials and Methods
Subjects
Plasma samples and associated clinical data were collected as
part of the Pharmacogenomic Evaluation of Antihypertensive
Response (PEAR) study, which is a prospective, randomized,
parallel group titration study undertaken in primary care patients
with mild to moderate essential hypertension. The objectives and
design of the PEAR study have been described previously [16].
Subjects of any self-defined race or ethnicity, aged 17–65 years,
were enrolled at the University of Florida (Gainesville, FL), Emory
University (Atlanta, GA), and the Mayo Clinic (Rochester, MN).
The study was approved by the institutional review board at each
institution, and all participants provided informed, written consent
prior to being screened for study participation. Enrolled subjects
had newly diagnosed, untreated or treated hypertension; if treated,
the antihypertensive(s) was discontinued with a minimum washout
of 18 days. Briefly, exclusion criteria included diastolic blood
pressure (DBP) .110 mm Hg or systolic blood pressure (SBP)
.180 mm Hg, secondary hypertension, cardiovascular disease,
diabetes, renal insufficiency (serum creatinine .1.5 in male
patients and .1.4 in female patients), liver enzymes .2.5 times
the upper limit of normal, and treatment with BP-raising drugs,
among others.
Study protocol
Enrolled subjects were randomly assigned at each study site to
receive hydrochlorothiazide or atenolol monotherapy; the focus of
the metabolomics analyses reported herein is the atenolol
monotherapy treatment arm. Atenolol was initiated at 50.0 mg
daily for 3 weeks and titrated to 100.0 mg daily on the basis of
blood pressure; treatment continued for an additional 6 weeks.
Blood pressure was assessed at baseline and after 9 weeks of
atenolol treatment by home-recorded blood pressure measure-
ments using a Microlife model 3AC1-PC home BP monitor (BP
Microlife, Minneapolis, MN). The device was set to measure BP in
triplicate with each activation and to store the average systolic and
diastolic BPs and the time of each set of measurements.
Plasma samples
Subjects included in the metabolomics analyses (n = 272) were
randomly selected from each quartile of blood pressure response,
defined as the difference in BP after atenolol treatment from the
BP at baseline. Subjects were balanced by race and to the extent
possible by sex. Pre- and post-treatment fasting plasma samples
were collected at baseline and after 9 weeks of atenolol treatment.
GC-TOF Mass Spectrometry
The study design was entered into the SetupX database [17].
Plasma samples were aliquotted and maintained at 280uC until
use, at which point 30 ml of plasma samples were thawed,
extracted and derivatized [18]. Briefly, 15 ml aliquots were
extracted with 1 ml of degassed acetonitrile:isopropanol:water
(3:3:2) at 220uC, centrifuged and decanted with subsequent
evaporation of the solvent to complete dryness. A clean-up step
with acetonitrile/water (1:1) removed membrane lipids and
triglycerides and the supernatant was again dried down. Internal
standards C8–C30 FAMEs were added and the sample was
derivatized with methoxyamine hydrochloride in pyridine and
subsequently by MSTFA (Sigma-Aldrich) for trimethylsilylation of
acidic protons.
A Gerstel MPS2 automatic liner exchange system was used to
inject 1 ml of sample at 50uC (ramped to 250uC) in splitless mode
with a 25 sec splitless time. An Agilent 6890 gas chromatograph
(Santa Clara, CA) was used with a 30 m long, 0.25 mm i.d.
Rtx5Sil-MS column with 0.25 mm 5% diphenyl film; an additional
10 m integrated guard column was used (Restek, Bellefonte PA).
Chromatography was performed at a constant flow of 1 ml/min,
ramping the oven temperature from 50uC for to 330uC over
22 min. Mass spectrometry used a Leco Pegasus IV time of flight
mass (TOF) spectrometer with 280uC transfer line temperature,
electron ionization at 270 V and an ion source temperature of
250uC. Mass spectra were acquired from m/z 85–500 at 20
spectra/sec and 1750 V detector voltage. Result files were
exported to our servers and further processed by our metabo-
lomics BinBase database. All database entries in BinBase were
matched against the Fiehn mass spectral library of 1,200 authentic
metabolite spectra using retention index and mass spectrum
information or the NIST05 commercial library. Identified
metabolites were reported if present with at least 50% of the
samples per study design group (as defined in the SetupX
database). Quantitative data were normalized to the sum
intensities of all known metabolites and used for statistical
investigation.
Genotyping of Lipase Candidate Genes
Genotypes of 16 lipase genes were obtained from the Illumina
Human 50 K cardiovascular chip [19], a customized gene-centric
array including ,2100 genes and ,50,000 SNPs genotyped using
the Infinium II Assay (Illumina, San Diego, CA). Genotypes were
called using GenomeStudio software version 2011.1 and the
Genotyping Module version 1.9 calling algorithm (Illumina, San
Diego, CA). Participants were excluded if sample genotype call
rates were below 95% and SNPs were excluded if genotype call
rates were below 90%. Sample contamination was detected by
checking gender mismatches using X chromosome genotype data
and cryptic relatedness was estimated by pairwise identity-by-
descent (IBD) analysis implemented using PLINK [20]. After the
QC procedures, the total SNP call rate in the remaining
individuals was 99.799%. Hardy-Weinberg equilibrium was
Ethnic Differences in Exposure to Atenolol
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assessed by chi-square test with one degree of freedom. There were
463 SNPs included in the genetic association analysis.
Data Analysis
A Wilcoxon signed rank test was used to detect metabolites that
were significantly changed by drug treatment. The difference in
metabolic change between two race groups, Caucasian and
African American, was evaluated using a Wilcoxon rank sum
test. Q-values [21] were calculated to control for multiple testing
false discovery rate (FDR). Correlation matrixes were used to
visualize the correlation between metabolites. The modulated
modularity clustering algorithm [22] was used to cluster metab-
olites based on their pairwise Spearman’s correlation coefficients.
Pathways and networks were analyzed using multiple approaches.
MetaMapp [23] was used to calculate metabolic networks, which
were displayed using Cytoscape [24]. Multiple databases were
used in the process of data analysis. These included KEGG [25]
and PharmGKB [26].
Associations of the 463 SNPs in the lipase genes with oleic acid
response to atenolol monotherapy were evaluated using linear
regression, adjusting for baseline oleic acid, age, gender and the
first 2 principal components for ancestry, which correspond to
European and African ancestry, respectively. P values of ,0.0001
(0.05/463) were considered statistically significant. Genetic asso-
ciation analysis was performed using PLINK [20] assuming
additive mode of inheritance.
Network Modeling
The process for constructing a model based upon metabolomics
data is quite different from the process for proteomics, transcrip-
tomics or genomics datasets. This is because concept or text-based
associations (for example GO categories or MESH headings) are
not associated with small molecule compounds as they are for
proteins or genes. While pathway databases such as KEGG can be
used to deduce some mechanisms, the available data are extremely
limited. For example, only a fraction of the known human
metabolome is linked to pathways, and secondary processes such
as gut microbiome-generated effects [27] and much of lipid
metabolism are not included. For this reason, less direct methods
using existing tools must be used for pathway and network analysis
for complex studies. The approach used MetaMAPP [28], a
network modeling tool that uses KEGG reaction pairs (e.g.
standard metabolic pathways) and then adds compounds, which
are not on these pathways, by chemical similarity (Tanimoto)
index [29].
Results
Baseline characteristics according to race for the PEAR
participants included in this metabolomics study are described in
Table 1. GC-TOF data from plasma samples collected before and
after 9 weeks of atenolol treatment were analyzed; a total of 544
samples from 272 patients were analyzed. Analysis of plasma on
the GC-TOF platform resulted in a total of 157 identified
compounds after processing in BinBase. These included amino
acids, sugars and sugar alcohols, fatty acids and cholesterol,
organic anions, including TCA cycle intermediates, and many
other compounds. There were 171 additional compounds in the
dataset that were observed and annotated but not identified.
Metabolomic Signature of Atenolol Treatment
Study participants on average had expected physiological and
metabolic changes over a course of atenolol therapy (Table 2).
Systolic and diastolic blood pressure decreased, along with LDL,
HDL and plasma renin activity in both Caucasians and African
American patients. Glucose, triglycerides and uric acid increased
significantly over the course of the 9 weeks. As expected, there
were significant difference between Caucasians and African
Americans in blood pressure and plasma renin activity change
in response to atenolol monotherapy (Table 2).
Seventeen metabolites had a nominally significant change in
plasma levels upon atenolol treatment; nine changed significantly
in the complete dataset after considering false discovery rate
(Table 3) seven of which were fatty acids. Four of these fatty acids,
myristic, methylhexadecanoic, palmitic and stearic acids are
saturated, whereas palmitoleic and oleic are monounsaturated;
arachidonic acid and linoleic are polyunsaturated. These struc-
turally diverse fatty acids decreased in concentration significantly
over the treatment period. Many free fatty acids, such as
arachidonic acid, oleic, linoleic and palmitic, are non-covalently
bound in large quantities to human serum albumin [30]. Fatty
acid changes correlated strongly with each other in the total
population (Figure 1). Some fatty acids, including the saturated
fatty acids lauric (12:0) and capric (10:0), caprylic acid (8:0),
pentadecanoic acid (15:0), and azelaic acid, a saturated dicarbox-
ylic acid, remained unchanged by atenolol treatment across
categories. Elaidic acid (18:1 trans-9), the trans isomer of oleic
acid, was not changed.
The ketone body 3-hydroxybutyrate was significantly reduced
upon atenolol treatment in the complete dataset. Two other
ketone bodies, acetone and acetoacetate, were not measured in the
experiment. The sugar alcohol threitol and the essential amino
acid threonine (marginal significance) were also reduced upon
atenolol treatment in the combined dataset.
Atenolol treatment did not change the levels of glycerol or
glycerol-3-phosphate, either in the combined data or after
separating Caucasians and African Americans. Lipids that
remained unchanged upon atenolol treatment included alpha
and gamma tocopherol and cholesterol.
The observed metabolic changes were modeled by constructing
a metabolic network using KEGG reaction pairs and structural
(Tanimoto) distances, using in part the software MetaMAPP [28]
and Cytoscape [24]. This allows for visualization of metabolic
changes and the determination of how observed compounds are
connected by pathways (Figure 2).
Table 1. Baseline Characteristics of Study Participants
According to Race (n = 272).
Characteristics Caucasians (n =150)
African Americans
(n=122)
Age, years 50.469.5 46.968.7
Men, n (%) 74 (49.3%) 31 (25.4%)
Weight, kg 88.7617.3 88.2618.1
BMI, kg/m2 30.565.9 31.566.5
Waist circumference, cm 97.7612.7 96.6613.8
Hip circumference, cm 109.0610.8 113.5614.3
Continuous variables are presented as mean 6 standard deviation;
Categorical variables are presented as numbers and percentage.
BMI: body mass index.
doi:10.1371/journal.pone.0057639.t001
Ethnic Differences in Exposure to Atenolol
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Metabolomic Signature of Atenolol Treatment Differs in
Caucasians and African Americans
There were large differences in the metabolic response to
atenolol between Caucasians and African Americans. Many of the
changes that appear in the total population (Table 3) are the result
of significant changes in the Caucasian population, but not in the
African American population (Table 4). Saturated (palmitic),
monounsaturated (oleic, palmitoleic) and polyunsaturated (arachi-
donic, linoleic) free fatty acids all decreased in Caucasians with
atenolol treatment after correction for false discovery rate (FDR)
with Q-value ,0.05. None of these compounds changed
significantly in African Americans after correcting for FDR.
Similarly, when the data were broken down by race, the reduction
in the ketone body 3-hydroxybutyrate was significant in Cauca-
sians with a 33% change but not African American individuals
(Table 4).
Genetic associations
The fatty acid signature of atenolol suggested that lipases might
be regulated differently in Caucasians and African Americans and
genetic variation might contribute to the differences observed. We
therefore tested the association between the top atenolol treatment
Table 2. Comparison of clinical metabolic parameters for atenolol monotherapy (N = 272) for Caucasians and African Americans.
Caucasians (n=150) African Americans (n =122) C vs. AA*
Baseline
Post-
Treatment D P Baseline Post-Treatment D P P
SBP mm Hg 145.169.8 133.6612.5 211.4869.62 ,0.0001 144.8610.7 142.2613.6 22.63610.57 0.007 ,0.0001
DBP mm Hg 92.465.7 82.267.4 210.2766.77 ,0.0001 93.966.6 89.968.6 24.0266.50 ,0.0001 ,0.0001
Glucose mg/dl 91.7610.6 94.5610.1 2.7369.11 0.0003 89.1610.9 92.0614.8 2.88613.47 0.0197 0.33
LDL mg/dl 121.7630.3 118.2630.7 23.48620.35 0.038 122.3631.0 121.5633.9 20.83617.85 0.61 0.81
HDL mg/dl 47.9612.5 45.2611.7 22.7366.60 ,0.0001 55.2617.6 52.2616.5 23.0267.52 ,0.0001 0.91
Triglyceride mg/dl 138.1680.3 164.06133.4 25.85679.48 0.0001 93.3662.7 107.0665.4 13.74637.80 0.0001 0.17
Uric Acid mg/dl 5.4361.30 5.7161.25 0.2860.60 ,0.0001 5.4461.36 5.7061.33 0.2660.71 ,0.0001 0.84
Plasma Renin
Activity, ng/ml/h
1.2361.36 0.4860.61 20.7761.22 ,0.0001 0.6160.59 0.3460.43 20.2660.56 ,0.0001 ,0.0001
All variables are presented as mean 6 standard deviation.
D: difference between baseline and post-treatment.
AA: African Americans.
*C vs. AA: p-value for Caucasians vs. African Americans.
doi:10.1371/journal.pone.0057639.t002
Figure 1. Heat map showing the correlation of the change in a
subset of metabolite concentrations with each other. The fatty
acids correlate with each other but not with threitol or alpha-
ketoglutaric acid.
doi:10.1371/journal.pone.0057639.g001
Table 3. Identified compounds that change significantly after
atenolol treatment in Caucasians and African Americans
(n = 272).
Compound % change p-value Q value
oleic acid (18:1 cis-9) 217.1 1.18E-07 5.43E-05
linoleic acid (18:2 n-6) 212.8 1.06E-06 2.44E-04
palmitoleic acid (16:1) 215.4 2.51E-05 3.85E-03
palmitic acid (16:0) 29.1 3.42E-05 3.93E-03
3-hydroxybutanoic acid 216.4 4.268E-05 3.93E-03
arachidonic acid (20:4 v-6) 29.5 4.33E-04 0.031
threitol 6.6 4.67E-04 0.031
methylhexadecanoic acid
(17:0)
27.4 6.16E-04 0.035
alpha ketoglutaric acid 9.4 9.26E-04 0.046
myristic acid (14:0) 24.1 7.95E-03 0.247
threonine 27.1 8.30E-03 0.247
arabitol 4.0 8.57E-03 0.247
stearic acid (18:0) 28.1 0.015 0.295
dihydroabietic acid 5.1 0.031 0.474
glycerol-alpha-phosphate 27.1 0.041 0.528
conduritol-beta-epoxide* 6.8 0.044 0.528
allo-inositol 5.5 0.049 0.574
Bold line indicates Q,0.05.
doi:10.1371/journal.pone.0057639.t003
Ethnic Differences in Exposure to Atenolol
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signature, oleic acid, and the SNPs on the 16 genes encoding
lipases on the cardiovascular SNP array. We found that an
intronic SNP (rs9652472) on LIPC, the hepatic lipase, was
associated with oleic acid response in Caucasians (p = 3.661024)
but not in African Americans (p = 0.40) after atenolol monother-
apy. We also found that an intronic SNP (rs7250148) on
PLA2G4C, phospholipase A2 group IVC, was associated with
oleic acid change in African Americans (p = 9.661025), but not in
Caucasians (p = 0.62).
Discussion
The aim of this study was to evaluate changes in the
metabolome induced by treatment with atenolol and determine
whether metabolomics provides novel mechanistic insight into
racial differences in drug response. Our findings revealed a strong
effect of atenolol on fatty acids that differed by race. Indeed, the
effects of atenolol were highly significant in Caucasians but absent
or minimal in African Americans. Further, we observed a race-
dependent genetic association between the changes in oleic acid
with SNPs in genes that encode lipases.
Figure 2. Metabolic network showing changes in Caucasian subjects that occur as a result of atenolol treatment after 9 weeks. Red
color indicates that compounds decrease significantly in concentration; green indicates compounds that increase significantly in concentration. Bold
blue lines indicate compounds related by a Kegg reaction pair, whereas others are related by structural similarity.
doi:10.1371/journal.pone.0057639.g002
Ethnic Differences in Exposure to Atenolol
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Overall changes and mechanism
We show for the first time a significant difference in the
metabolic signature of atenolol treatment between Caucasians and
African Americans. Looking at the global changes induced by
atenolol (Table 3 and Figure 1), there is a strong signature
consisting mainly of plasma free fatty acids, presumably involving
either a change in the relative rates of synthesis and/or
breakdown. Metabolic pathway analysis, described below, indi-
cates that these fatty acids are not related directly by synthetic
pathways (for example b-oxidation). Thus, alteration in a single
synthetic pathway could not account for the coordinated changes.
An effect on basal lipolysis would be the most obvious potential
mechanism for the major changes in fatty acids observed here: the
hydrolysis of triglycerides to free fatty acids and glycerol, followed
by further fatty acid breakdown via beta oxidation. Lipolysis is
stimulated by hormones, including epinephrine and norepineph-
rine, and is up-regulated by the b-adrenergic receptors and down-
regulated by a2-adrenergic receptors. Epinephrine, a non-specific
beta-adrenergic agonist, stimulates lipolysis via the b3-adrenore-
ceptor (ADRB3). Atenolol specifically, and b-blockers generally,
have an effect on plasma lipoprotein metabolism by increasing
plasma triglyceride levels and decreasing HDL but not affecting
LDL [31]. The effect on triglycerides is smaller with atenolol than
propanolol, likely due to the relative b1-receptor selectivity of
atenolol [31]. Both atenolol and propanolol have been shown to
reduce free fatty acid levels [32]. If the reduction in plasma fatty
acids were due primarily to general lipolysis, then a corresponding
change in both plasma glycerol and glycerol-3-phosphate levels
would also be expected, as these are products of triglyceride
breakdown. Perhaps the endogenous levels of these compounds
are sufficiently large relative to the change in their levels so as to
mask the change from observation.
A second possible mechanism for the fatty acid changes
observed may be the direct effect of atenolol on phospholipase
activity (Figure 3). This mechanism is conceptually similar to that
of changes in lipolysis, although the upstream signaling interaction
would be different. There is circumstantial evidence suggesting
that b-blockers inhibit lysosomal phospholipase A and C [33].
Atenolol specifically has been found to inhibit lysosomal
phospholipase A1, although with less potency than propanolol
[34]. This suggests the possibility of a specific mechanism in which
atenolol may bind to and inhibit particular phospholipases in
plasma or other related tissues (Figure 3). Atenolol has been shown
to bind to bee venom phospholipase A2 and form a stable
complex. This mechanism also allows for a potential explanation
of racial variance, as phospholipase activity has been shown to
vary as a function of both sex and race. Lipoprotein-associated
phospholipase A2 (Lp-PLA2), for example, was 15% lower in
African American individuals compared with Caucasian subjects
[35]. Higher concentrations of Lp-PLA2 are associated with
Table 4. Differences in the metabolic response of atenolol treatment between Caucasians and African Americans.
Compound Caucasians African-Americans
% change p-value Q value % change p-value Q value
oleic acid (18:1 cis-9) 221.1 1.88E-06 0.0009 29.2 0.007 0.41
linoleic acid (18:2 n-6) 216.2 4.77E-06 0.0011 29.6 0.019 0.54
3-hydroxybutanoic acid 233.3 5.03E-05 0.0080 211.5 0.059 0.67
palmitic acid (16:0) 29.1 1.12E-04 0.0134 26.2 0.062 0.67
palmitoleic acid (16:1) 216.2 3.75E-04 0.0285 25.4 0.022 0.56
arachidonic acid(20:4 v-6) 210.7 4.15E-04 0.0285 29.9 0.202 0.74
threitol 12.2 2.03E-03 0.1218 13.4 0.067 0.67
methylhexadecanoic acid 27.2 3.93E-03 0.2094 22.4 0.056 0.67
myristic acid (14:0) 29.5 0.023 0.5583 22.2 0.152 0.73
alpha ketoglutaric acid 10.5 0.033 0.6834 14.5 0.009 0.41
succinic acid 9.9 0.037 0.7066 20.7 0.736 0.85
trans-4-hydroxyproline 14.0 0.049 0.7673 10.7 0.848 0.88
The significant (p,0.05) changes in Caucasians are shown with the statistics of the corresponding compound in African Americans for comparison. Q-values are
corrected for FDR and the boxed section of the table highlights compounds with Q,0.05.
doi:10.1371/journal.pone.0057639.t004
Figure 3. Alternative model of a potential mechanism for
atenolol treatment on plasma free fatty acid concentrations.
doi:10.1371/journal.pone.0057639.g003
Ethnic Differences in Exposure to Atenolol
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e57639
increased cardiovascular risk, and cutoffs have been suggested
[36].
It has been shown that atenolol-modulated changes in lipids
involve more than simply a general adrenergic-mediated alteration
in lipolysis rate [37]. In cultured vascular smooth muscle cells,
atenolol induced a 61% increase in NAD+/NADH ratio and a
similar increase in the level of NADH-cytochrome b5 reductase
[38]. This protein is involved in desaturation and elongation of
fatty acids [39], as well as cholesterol biosynthesis [40], suggesting
that some of the observed changes could be caused by this enzyme.
The metabolite with the largest percent change was the ketone
body 3-hydroxybutyric acid, the concentration of which was
reduced by 33.3% in Caucasian individuals (p = 0.000050,
Q=0.0080) upon atenolol treatment but was not significantly
altered in African Americans (Table 4). Such a change could result
from either decreased production or increased utilization of 3-
hydroxybutyric acid, which is produced from acetyl-CoA as a
result of ketogenesis, mitochondrial free fatty acid b-oxidation
(breakdown), which occurs mostly in the liver [41]. This
production typically occurs during periods of low glucose levels,
when carbohydrate availability has been reduced. A concentration
change may reflect an alteration in the balance of energy usage
between carbohydrates and lipids. Note however that glucose
undergoes only a slight but significant increase (Table 2),
suggesting the 3-hydroxybutyric acid reduction could be the direct
result of the reduction in plasma free fatty acids upon atenolol
treatment.
Racial differences in Atenolol treatment
Differences in drug response between racial groups is increas-
ingly recognized as an important aspect of pharmacometabolo-
mics and, more generally, personalized health care [42–44].
Atenolol monotherapy is significantly less effective for blood
pressure lowering in patients of African origin than for Caucasian
patients [45]. While racial differences in plasma renin activity
associate with these differences in antihypertensive response, more
detailed understanding of the genetic or biochemical factors that
underpin these differences in response is needed.
While there is not a clear biochemical mechanism to explain the
metabolic differences observed in response to atenolol in
Caucasians compared to African Americans, there are differences
in lipid metabolism that may relate to specific mechanisms.
African Americans have on average higher plasma concentrations
of arachidonic acid compared with Caucasians, resulting from
genetic variants (SNP rs174537) in the fatty acid desaturase
enzyme (FADS gene cluster) that converts linoleic acid to
arachidonic acid [46]. For example, experiments on human
adipose tissue have shown that the basal lipolysis rate is
approximately 50% lower in obese African American women
than in Caucasian women and that this may be due to differences
in hormone-sensitive lipase enzyme levels [47]. The degree of
metabolic inflexibility, which relates to the ability of an individual
to switch substrate usage under different metabolic conditions, is
different in African American compared with Caucasian women.
Caucasians had higher rates of fat oxidation with lower rates of
carbohydrate oxidation during a high fat diet in comparison with a
low fat diet, whereas African Americans showed no difference
[48]. There are known racial differences in the blood pressure
response to atenolol between African American and Caucasian
patients [49–51]. Although physiological differences including
both blood pressure and heart rate in the response to atenolol have
been characterized between Caucasians and African Americans,
metabolic differences have not been previously associated with
race.
The racially disparate fatty acid signature induced by atenolol
suggested genetic variation may also contribute to the differences
observed between Caucasians and African Americans. We
therefore tested the association between the top fatty acid signal
oleic acid (Table 4) and SNPs on the 16 genes encoding lipases. In
Caucasians but not African Americans, the LIPC SNP rs9652472
was associated with oleic acid change (p = 3.661024), whereas in
African Americans but not Caucasians, the PLA2G4C SNP
rs7250148 was associated with oleic acid change (p = 9.661025).
Thus, the observed differences are explained at least in part by
genetic differences that may yield different activities in lipases and
corresponding differences in response to atenolol. These findings
are consistent with our pharmacometabolomics results indicating
that African Americans and Caucasians have distinct signatures in
response to atenolol monotherapy.
In summary, we showed that atenolol treatment causes a
marked change in plasma fatty acid levels in Caucasians but not
African Americans. We also showed that a SNP in the LIPC and
PLA2G4C genes were associated with the change in oleic acid in
Caucasians and African Americans, respectively. Specific race-
dependent changes in other metabolites such as the ketone body 3-
hydroxybutanoic acid and TCA cycle intermediate alpha
ketoglutaric acid need to be further investigated. Pharmacometa-
bolomics provides powerful tools to understand the mechanistic
basis of variation in response to drug therapy. It complements
information derived from pharmacogenomics and when com-
bined, enables a systems pharmacology approach to increase our
understanding of drug effects.
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